Cargando…

Novel Therapeutical Approaches to Managing Atherosclerotic Risk

Atherosclerosis is a multifactorial vascular disease that leads to inflammation and stiffening of the arteries and decreases their elasticity due to the accumulation of calcium, small dense Low Density Lipoproteins (sdLDL), inflammatory cells, and fibrotic material. A review of studies pertaining to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Giglio, Rosaria Vincenza, Pantea Stoian, Anca, Al-Rasadi, Khalid, Banach, Maciej, Patti, Angelo Maria, Ciaccio, Marcello, Rizvi, Ali A., Rizzo, Manfredi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8125277/ https://www.ncbi.nlm.nih.gov/pubmed/33924893 http://dx.doi.org/10.3390/ijms22094633

Ejemplares similares

Experimental and Emerging Free Fatty Acid Receptor Agonists for the Treatment of Type 2 Diabetes
por: Patti, Angelo Maria, et al.
Publicado: (2022)

Advances in the Pharmacological Management of Diabetic Nephropathy: A 2022 International Update
por: Giglio, Rosaria Vincenza, et al.
Publicado: (2023)

An Update on the Current and Emerging Use of Thiazolidinediones for Type 2 Diabetes
por: Giglio, Rosaria Vincenza, et al.
Publicado: (2022)

Effect of Semaglutide on Subclinical Atherosclerosis and Cardiometabolic Compensation: A Real-World Study in Patients with Type 2 Diabetes
por: Patti, Angelo Maria, et al.
Publicado: (2023)

Liraglutide Reduces Carotid Intima-Media Thickness by Reducing Small Dense Low-Density Lipoproteins in a Real-World Setting of Patients with Type 2 Diabetes: A Novel Anti-Atherogenic Effect
por: Nikolic, Dragana, et al.
Publicado: (2020)

Impact of Glucose-Lowering Medications on Cardiovascular and Metabolic Risk in Type 2 Diabetes
por: Patti, Angelo Maria, et al.
Publicado: (2020)

Natural approaches in metabolic syndrome management
por: Patti, Angelo Maria, et al.
Publicado: (2017)

Pasta Supplemented with Opuntia ficus-indica Extract Improves Metabolic Parameters and Reduces Atherogenic Small Dense Low-Density Lipoproteins in Patients with Risk Factors for the Metabolic Syndrome: A Four-Week Intervention Study
por: Giglio, Rosaria Vincenza, et al.
Publicado: (2020)

Nutraceuticals in the Management of Dyslipidemia: Which, When, and for Whom? Could Nutraceuticals Help Low-Risk Individuals with Non-optimal Lipid Levels?
por: Cicero, Arrigo F. G., et al.
Publicado: (2021)

Management of Statin Intolerance in 2018: Still More Questions Than Answers
por: Toth, Peter P., et al.
Publicado: (2018)

Lipoproteins and Cardiovascular Disease: An Update on the Clinical Significance of Atherogenic Small, Dense LDL and New Therapeutical Options
por: Rizvi, Ali A., et al.
Publicado: (2021)

Daily Use of Extra Virgin Olive Oil with High Oleocanthal Concentration Reduced Body Weight, Waist Circumference, Alanine Transaminase, Inflammatory Cytokines and Hepatic Steatosis in Subjects with the Metabolic Syndrome: A 2-Month Intervention Study
por: Patti, Angelo M., et al.
Publicado: (2020)

A New Look at Novel Cardiovascular Risk Biomarkers: The Role of Atherogenic Lipoproteins and Innovative Antidiabetic Therapies
por: Vekic, Jelena, et al.
Publicado: (2022)

Metabolic Syndrome: From Molecular Mechanisms to Novel Therapies
por: Rizvi, Ali Abbas, et al.
Publicado: (2021)

Liraglutide Improved Cardiometabolic Parameters More in Obese than in Non-obese Patients with Type 2 Diabetes: A Real-World 18-Month Prospective Study
por: Nikolic, Dragana, et al.
Publicado: (2022)

Liraglutide Increases Serum Levels of MicroRNA-27b, -130a and -210 in Patients with Type 2 Diabetes Mellitus: A Novel Epigenetic Effect
por: Giglio, Rosaria Vincenza, et al.
Publicado: (2020)

Endocrinology in the Time of COVID-19: A Rapid Evolution of Knowledge and Care
por: Rizvi, Ali A., et al.
Publicado: (2021)

Diabetes and Colorectal Cancer Risk: A New Look at Molecular Mechanisms and Potential Role of Novel Antidiabetic Agents
por: Vekic, Jelena, et al.
Publicado: (2021)

Effect of Oral Semaglutide on Cardiovascular Parameters and Their Mechanisms in Patients with Type 2 Diabetes: Rationale and Design of the Semaglutide Anti-Atherosclerotic Mechanisms of Action Study (SAMAS)
por: Janić, Miodrag, et al.
Publicado: (2022)

The Role of Advanced Glycation End Products on Dyslipidemia
por: Vekic, Jelena, et al.
Publicado: (2023)

Use of Novel Antidiabetic Agents in Patients with Type 2 Diabetes and COVID-19: A Critical Review
por: Popovic, Djordje S., et al.
Publicado: (2021)

A Critical View over the Newest Antidiabetic Molecules in Light of Efficacy—A Systematic Review and Meta-Analysis
por: Salmen, Teodor, et al.
Publicado: (2023)

COVID-19 and diabetes management: What should be considered?
por: Ceriello, Antonio, et al.
Publicado: (2020)

Reconnoitering the Therapeutic Role of Curcumin in Disease Prevention and Treatment: Lessons Learnt and Future Directions
por: Sivani, Bala Mohan, et al.
Publicado: (2022)

Promoting a Syndemic Approach for Cardiometabolic Disease Management During COVID-19: The CAPISCO International Expert Panel
por: Al Mahmeed, Wael, et al.
Publicado: (2021)

Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study
por: Rizzo, Manfredi, et al.
Publicado: (2016)

Editorial: Diet-microbe-host interactions in metabolic syndrome
por: Gradisteanu Pircalabioru, Gratiela, et al.
Publicado: (2023)

The Dual Pandemics of COVID-19 and Obesity: Bidirectional Impact
por: Kapoor, Nitin, et al.
Publicado: (2022)

Telemedicine for diabetes management during COVID-19: what we have learnt, what and how to implement
por: Rosta, Laszlo, et al.
Publicado: (2023)

Bergamot Reduces Plasma Lipids, Atherogenic Small Dense LDL, and Subclinical Atherosclerosis in Subjects with Moderate Hypercholesterolemia: A 6 Months Prospective Study
por: Toth, Peter P., et al.
Publicado: (2016)

A Nutraceutical Containing Chlorogenic Acid and Luteolin Improves Cardiometabolic Parameters in Subjects with Pre-obesity: A 6-Month Randomized, Double-Blind, Placebo-Controlled Study
por: Terzo, Simona, et al.
Publicado: (2023)

Post-COVID syndrome, inflammation, and diabetes()
por: Rizvi, Ali A., et al.
Publicado: (2022)

The Relationship between COVID-19 and Hypothalamic–Pituitary–Adrenal Axis: A Large Spectrum from Glucocorticoid Insufficiency to Excess—The CAPISCO International Expert Panel
por: Jensterle, Mojca, et al.
Publicado: (2022)

Novel Pharmaceutical and Nutraceutical-Based Approaches for Cardiovascular Diseases Prevention Targeting Atherogenic Small Dense LDL
por: Vekic, Jelena, et al.
Publicado: (2022)

Molecular and pro-inflammatory aspects of COVID-19: The impact on cardiometabolic health
por: Lo Presti, Elena, et al.
Publicado: (2022)

Atherosclerosis Development and Progression: The Role of Atherogenic Small, Dense LDL
por: Vekic, Jelena, et al.
Publicado: (2022)

Antidiabetic Molecule Efficacy in Patients with Type 2 Diabetes Mellitus—A Real-Life Clinical Practice Study
por: Salmen, Teodor, et al.
Publicado: (2023)

Fibrinogen and Atherosclerotic Cardiovascular Diseases—Review of the Literature and Clinical Studies
por: Surma, Stanisław, et al.
Publicado: (2021)

Current Pharmacological Treatment of Painful Diabetic Neuropathy: A Narrative Review
por: Ardeleanu, Valeriu, et al.
Publicado: (2020)

The effects of statins on blood pressure: current knowledge and future perspectives
por: Rizzo, Manfredi, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_g5aocpenkkscc3l2lgrntvg6od